Key Findings From Recent Trials

Basic Prometrium Information

• INN (International Nonproprietary Name): Progesterone
• Brand Names Available In United States: Prometrium (capsules 100 mg, 200 mg; 30/90-count blisters, orange/yellow)
• ATC Code: G03DA04
• Forms & Dosages: Soft capsules 100 mg and 200 mg in blister packs (30/90), vaginal capsules/softgels 100 mg and 200 mg, and rare compounding powders (variable)
• Manufacturers In United States: AbbVie (Prometrium); generics available from multiple manufacturers internationally
• Registration Status In United States: FDA-approved for secondary amenorrhea and for endometrial protection in postmenopausal women receiving estrogens
• OTC / Rx Classification: Prescription only (Rx)

What should clinicians and patients take away from trials since 2022?

Micronized oral progesterone—marketed as Prometrium in the United States and Utrogestan in parts of Europe—has been the focus of new studies for endometrial protection in HRT, luteal support in assisted reproduction, and treatment for secondary amenorrhea.

Recent work reinforced two consistent clinical trends: effective endometrial protection when micronized progesterone is paired with estrogens at standard regimens, and dose-ranging assessments that examined 100–400 mg capsules for cycle control and amenorrhea.

Large observational cohorts and randomized controlled trials reported fewer androgenic and metabolic signals with natural micronized progesterone compared with synthetic progestins such as medroxyprogesterone, while noting the need for careful interpretation because administration routes and local off-label uses varied across regions.

Major 2022–2026 Studies

Which trials shaped practice between 2022 and 2026?

Study designs included large observational cohorts and randomized controlled trials focused on micronized progesterone for three main uses: endometrial protection in postmenopausal HRT, luteal support during ART, and secondary amenorrhea treatment.

Trial comparisons frequently assessed micronized oral progesterone against synthetic progestins like medroxyprogesterone, and also explored dose-ranging (100–400 mg) to define efficacy and tolerability.

Main Outcomes

What outcomes were measured and what changed clinical practice?

Micronized progesterone at standard regimens produced reliable endometrial protection when combined with estrogen therapy, with common regimens including 200 mg nightly for 12 days per 28-day cycle for postmenopausal HRT.

For secondary amenorrhea, the labeled regimen of 400 mg orally at bedtime for 10 days continued to demonstrate predictable withdrawal bleeding and cycle control when repeated monthly as prescribed.

Dose-ranging work helped characterize tolerability and amenorrhea control across 100–400 mg capsules, with higher doses used for amenorrhea and lower doses used for luteal support or cycle control in some protocols.

Safety Observations

What safety signals appeared in recent trials?

Safety themes repeated across studies included hepatic caution—micronized progesterone is contraindicated in severe hepatic dysfunction—and thrombotic risk monitoring in patients with cardiovascular or clotting histories.

Comparative data showed fewer androgenic and metabolic adverse signals with natural progesterone compared with some synthetic progestins, but thromboembolic and hepatic precautions remained central to patient selection.

Packaging and excipient issues were highlighted, notably that US capsules may contain peanut oil and require appropriate allergy warnings and counseling.

Clinical Mechanism Of Action

Layman’s Explanation

What does progesterone do in simple terms?

Progesterone tells the uterus to stop building the lining and to switch into a maintenance mode that supports a secretory-phase endometrium rather than continued growth.

When given with estrogen for postmenopausal hormone therapy, it prevents the endometrium from over-proliferating and lowers the risk of endometrial hyperplasia.

Progesterone metabolites in the brain can act like natural calming agents, which explains common effects on sleep and mood for some patients.

Scientific Breakdown

How does micronized progesterone work at the tissue level?

Progesterone is a pregnane steroid that binds to progesterone receptor isoforms PR-A and PR-B in target tissues such as the endometrium, breast, and central nervous system.

Activation of PR-A/PR-B induces a secretory transformation of the endometrium and opposes estrogen-driven proliferation, producing a histologic pattern consistent with luteal-phase endometrium.

In the brain, hepatic metabolism of progesterone generates neuroactive metabolites, including allopregnanolone, which positively modulate GABA-A receptors and contribute to sedative and mood-modulating effects.

Pharmacokinetics And Formulation Notes

How does formulation affect absorption and effect?

Micronized oral capsules (Prometrium in the United States; Utrogestan in Europe) use micronized progesterone in oil-filled soft capsules to enhance oral bioavailability compared with crude progesterone powder.

Common strengths are 100 mg and 200 mg softgels, often taken at bedtime to take advantage of sedative effects and to minimize daytime drowsiness.

Tissue Effects And Metabolism

What happens after ingestion?

Oral micronized progesterone undergoes hepatic metabolism to active neurosteroids that act systemically and centrally.

Because of liver metabolism, Prometrium is contraindicated in severe hepatic dysfunction per product labeling, and clinicians should exercise caution in patients with significant liver disease.

Scope Of Approved & Off-Label Use

United States Approvals

What does the FDA approve Prometrium for?

Prometrium (micronized progesterone) is FDA-approved for two primary indications: secondary amenorrhea and endometrial protection in postmenopausal women receiving estrogen therapy.

The typical approved regimen for secondary amenorrhea is 400 mg orally once daily at bedtime for 10 days, repeated monthly as prescribed.

The standard dose for endometrial protection in postmenopausal hormone replacement therapy is 200 mg orally once daily at bedtime for 12 days of a 28-day cycle when combined with estrogens.

Notable Off-Label Trends

How do clinicians use Prometrium beyond label indications?

Off-label practices reported in Europe and parts of Asia include vaginal insertion of oral capsules to improve local endometrial exposure for luteal support or in assisted reproduction protocols, though this use is not universally registered and complicates pooled analyses.

Compounded formulations and institution-specific regimens are used for individualized dosing in ART, and some patients receive progesterone principally for sleep or mood symptoms despite these uses lacking formal approval.

Clinicians must weigh regulatory status, trial evidence, and excipient concerns—such as peanut oil in US capsules—when recommending off-label administration routes or formulations.

Dosage Strategy

General Dosing

How is Prometrium typically dosed in practice?

Micronized progesterone softgels are commonly taken at bedtime to reduce daytime drowsiness and to match label guidance that uses evening dosing for key regimens.

Available strengths are 100 mg and 200 mg soft capsules, allowing flexible regimens for cyclic or short-course therapy.

Condition-Specific Dosing

What are the labeled doses for common indications?

• Secondary Amenorrhea: 400 mg orally once daily at bedtime for 10 days, repeat monthly as prescribed.
• Endometrial Protection (Postmenopausal HRT): 200 mg orally once daily at bedtime for 12 days of a 28-day cycle when combined with estrogens.
• Luteal Support/ART: Regimens vary; common clinical practice uses 100–200 mg twice daily or vaginal insertion, but many protocols are off-label or institution-specific.

Are dose adjustments needed?

Prometrium is contraindicated in severe hepatic dysfunction, and dose adjustments are not established for children because safety and efficacy have not been established for pediatric use.

Elderly patients have no specific labeled adjustment, but increased sensitivity should be monitored in clinical follow-up.

Safety Protocols

Contraindications

Who should not take micronized progesterone?

• Severe liver dysfunction (contraindicated).
• Known or suspected breast cancer or other hormone-dependent malignancy.
• Undiagnosed abnormal vaginal bleeding.
• Current or past history of thrombosis (DVT, PE, stroke, myocardial infarction).
• Allergy to peanuts—US capsules may contain peanut oil.
• Certain pregnancy situations per labeled guidance.

Adverse Effects

What side effects should patients expect?

The most common mild to moderate adverse effects are headache, breast tenderness, abdominal cramps or bloating, dizziness, fatigue and daytime drowsiness, mood changes including irritability, weight changes, nausea, and musculoskeletal pain.

In overdose scenarios symptoms can include nausea, vomiting, withdrawal bleeding, and sedation, and treatment is supportive with prompt consultation with a medical provider.

Monitoring suggestions include baseline liver function assessment in patients at risk and thrombotic risk evaluation prior to initiating long-term therapy.

Interaction Mapping

Food Interactions

Does food affect absorption?

Micronized progesterone is delivered in an oil-filled softgel, and lipid content of a meal can influence oral bioavailability.

Bedtime dosing is standard both to reduce daytime sedation and because many labels advise taking the drug with or without food at night to balance absorption and tolerability.

Drug Combinations To Avoid

What drugs should be monitored or avoided?

Strong CYP3A4 inducers may reduce progesterone exposure, and strong CYP3A4 inhibitors may increase exposure; monitoring is advisable when such agents are co-prescribed.

Concomitant estrogen is common in HRT; when used together, cyclic progesterone (200 mg x12 days/28-day cycle) is required for endometrial protection.

Patients with anticoagulant use or a history of thrombosis require specialist coordination because of thrombotic risk considerations.

Always check for excipient allergies—peanut oil in US Prometrium capsules necessitates avoidance in those with severe peanut allergy.

Patient Experience Analysis

Survey Data

How do patients report tolerability and satisfaction?

Patient-reported outcome surveys and online pharmacy data indicate that many patients prescribed Prometrium report good efficacy for cycle control and for HRT endometrial protection when dosed per label.

Common patient complaints involve daytime drowsiness (often mitigated by taking the capsule at bedtime), mood changes, and breast tenderness.

Forum Trends

What do patients discuss online?

Forums and social communities frequently discuss off-label vaginal use of oral capsules (more common in Europe and Asia), compounding for individualized dosing in ART, and brand differences between Prometrium and Utrogestan or other international brands.

Practical concerns raised by patients include cost and insurance coverage, prescription access because the product is Rx-only in official registrations, peanut oil allergen concerns, and storage or travel considerations such as keeping the capsules below 25°C and protected from moisture.

Distribution & Pricing Landscape

Where does Prometrium come from and what affects price?

Major manufacturers include AbbVie for Prometrium in the United States and Besins Healthcare for Utrogestan in Europe, with multiple generics and suppliers such as Teva, Mylan, Alkem, and Medochemie active in international markets.

Prometrium in the United States is commonly supplied as 100 mg and 200 mg capsules in blister packs of 30 or 90 units with orange/yellow packaging.

Pricing drivers include brand versus generic status, capsule strength, insurance coverage, and whether compounding or off-label dosing is required—these can increase out-of-pocket costs.

US packaging must include peanut allergen labeling, and storage guidance (keep below 25°C and protect from moisture and light) affects pharmacy stocking and shipping practices.

In our online pharmacy, prometrium is available without a prescription, with discreet delivery to United States in 5-14 days.

Alternative Options

Comparison Table

How does micronized progesterone compare with other progestogens?

• Micronized Progesterone (Prometrium/Utrogestan): Natural progesterone, physiologic receptor profile, fewer androgenic/metabolic effects, available as soft capsules 100/200 mg; cons include sedation and peanut oil excipient in US capsules.
• Medroxyprogesterone (Provera): Synthetic progestin available as oral tablets and injectable forms; pros include stable dosing and established protocols; cons include differing metabolic and androgenic side-effect profiles.
• Dydrogesterone (Duphaston): Oral synthetic progestin structurally distinct with different pharmacology and availability by market.
• Generic Micronized Progesterone: Same active ingredient as Prometrium but excipients and source may vary.

Pros And Cons

Which option fits which patient?

Choice depends on indication (HRT endometrial protection vs secondary amenorrhea vs ART), comorbidities (liver disease, thrombotic risk, peanut allergy), cost and access, and desired route of administration.

Regulatory Status

US & EMA Approvals

What do regulators say?

The FDA in the United States approves Prometrium for secondary amenorrhea and for endometrial protection in postmenopausal women receiving estrogen therapy.

The EMA and national agencies in Europe authorize micronized progesterone under brand names such as Utrogestan, often labeled with local terms like “micronisé” or “micronised.”

Country-Specific Notes

Are there meaningful differences by country?

Packaging and brand names vary—Prometrium in the US and Canada, Utrogestan in many EU countries, and other local brands such as Progeffik or Progestan in some countries.

In parts of Europe and Asia, vaginal use of oral capsules is common in clinical practice despite being off-label in many jurisdictions, so clinicians should verify local marketing authorizations before recommending unlicensed routes.

Consolidated FAQ

Dosing & Timing

How should patients take Prometrium?

Bedtime dosing is recommended to reduce daytime sedation.

For secondary amenorrhea, the labeled regimen is 400 mg nightly for 10 days, repeated monthly as prescribed.

For endometrial protection in postmenopausal HRT, use 200 mg nightly for 12 days of a 28-day cycle when combined with estrogen therapy.

If a dose is missed, take it as soon as remembered unless the next dose is due soon; do not double doses.

Safety & Monitoring

What safety checks are needed?

Do not use in severe hepatic dysfunction or in patients with known hormone-dependent malignancy, and avoid in those with active or past thrombotic disease.

Assess thrombotic and hepatic risk before initiating therapy, and counsel patients to seek immediate care for chest pain, shortness of breath, sudden leg swelling or pain, or signs of jaundice.

Storage: keep below 25°C, protect from moisture and light, and keep in original blister packaging. Do not refrigerate.

Visual Guide

Packaging Differences

How do packages differ across markets?

Prometrium in the United States and Canada typically comes in orange/yellow blister packs, 100 mg and 200 mg softgels in counts of 30 or 90.

Utrogestan in Europe often appears as softgels labeled “micronisé” or “micronised” and may carry different box art and language-specific labeling.

Administration Visuals

What should patients see on the label or understand about administration?

Capsule sizes vary by strength; clear labeling for bedtime dosing is common on US packaging and an allergen icon for peanut oil will appear when required.

Storage & Transport Graphic Elements

Key icons to include: store below 25°C, protect from moisture and light, do not refrigerate.

Off-Label Vaginal Use Depiction

Off-label vaginal insertion of oral capsules is practiced in parts of Europe and Asia, but it is off-label in many regions and should only be shown with a clear disclaimer and local guidance.

Storage & Transport

Pharmacy Handling

How should pharmacies manage stock?

Store Prometrium capsules below 25°C and protect blister packs from moisture and light.

Keep stock rotation by expiration date and ensure dispensing labels note peanut allergen warnings in US dispensing materials.

Patient Guidance

What should patients know about keeping their medication safe?

Keep capsules in their original blister until use, avoid storing in bathrooms or other humid environments, and discard if exposed to heat or moisture that could degrade the capsule.

For international mail-order, verify local customs and regulatory requirements because Prometrium/Utrogestan remain prescription-only in most jurisdictions.

Guidelines For Proper Use

Prescriber Checklist

What should prescribers confirm before writing a prescription?

1. Confirm the indication: secondary amenorrhea or endometrial protection with estrogen therapy.
2. Screen for absolute contraindications: severe liver dysfunction, hormone-dependent malignancy, undiagnosed vaginal bleeding, current or history of thrombosis, peanut allergy.
3. Select the appropriate dose: 400 mg x10 days for secondary amenorrhea or 200 mg x12 days per 28-day cycle for endometrial protection.
4. Evaluate drug interactions and hepatic function as indicated, and document informed consent for off-label uses.

Patient Counseling Points

What should pharmacists tell patients at dispensing?

Emphasize bedtime dosing to limit drowsiness, review expected side effects such as dizziness, breast tenderness, and mood changes, and advise when to seek urgent care for signs of thrombosis or liver dysfunction.

Reinforce storage instructions (below 25°C, protect from moisture/light), missed-dose rules, and the presence of peanut oil in US capsules as a potential allergen.

Visual Guide

Packaging Differences

US packaging: Prometrium orange/yellow blister packs in 30 or 90 counts.

EU packaging: Utrogestan softgels often labeled “micronisé” or “micronised.”

Administration Visuals

Show capsule options (100 mg vs 200 mg), bedtime dosing notation, and allergen icon for peanut oil where required.

Delivery Across United States

Concluding Notes

What matters most when choosing micronized progesterone?

Micronized progesterone (Prometrium) provides physiologic progesterone replacement with label-supported regimens for secondary amenorrhea and endometrial protection during postmenopausal estrogen therapy.

Clinicians should balance efficacy with safety: screen for hepatic disease, thrombotic history, and peanut allergy, and use bedtime dosing to mitigate drowsiness.

Off-label practices such as vaginal insertion and compounded formulations exist and are used in reproductive medicine, but prescribers must document rationale and obtain informed consent when deviating from local marketing authorizations.

Pharmacies should confirm brand expectations (Prometrium vs Utrogestan), advise on excipient warnings, and follow storage and transport guidance to preserve product integrity.

For routine questions about dosing, interactions, availability, or shipping to a patient’s address, contact a licensed pharmacist or the prescribing clinician to review individualized therapy.